A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE Mono-2
- Sponsors Pfizer
- 20 Jul 2018 Planned End Date changed from 1 Aug 2019 to 13 Aug 2019.
- 20 Jul 2018 Planned primary completion date changed from 1 Aug 2019 to 13 Aug 2019.
- 12 Jul 2018 Planned End Date changed from 13 Jun 2019 to 1 Aug 2019.